Comprehensive information about experimentally validated enhancers
| Enhancer ID: | E_03190 |
| Species: | Mus musculus |
| Position : | chr5:107680655-107682655 |
| Year: | 2013 |
| Title: | The control of hematopoietic stem cell maintenance, self-renewal, and differentiation by Mysm1-mediated epigenetic regulation. |
| Genome Build: | mm10 |
| Enhancer Type: | Enhancer |
| Condition: | Normal |
| PMID: | 24014243 |
| Tissue: | bone marrow |
| Tissue Ontology ID: | UBERON:0002371 |
| Cell Source: | Mysm1-deficient HSCs |
| Cell Type: | hematopoietic stem cell |
| Cell Ontology ID: | CL:0000037 |
| Experiment Type: | Epigenetic enhancer regulation; TF occupancy; functional transactivation; Endogenous enhancer perturbation; In vivo functional validation |
| High Throughput Method: | ChIP-seq / expression profiling |
| Low Throughput Method: | ChIP-qPCR; enhancer reporter assay; TF transactivation; RT-qPCR; Mouse genetic deletion/knock-in |
| Target gene : | Gfi1 |
| TF name : | Runx1 |
| Regulatory State : | Active |
| GeneName | Pathway Name | Source | Gene Number |
|---|---|---|---|
| Runx1 | AndrogenReceptor | netpath | 167 |
| Runx1 | Organic cation transport | reactome | 9 |
| Runx1 | RANKL | netpath | 84 |
| Runx1 | Regulation of nuclear SMAD2/3 signaling | pid | 82 |
| Runx1 | TGF_beta_Receptor | netpath | 220 |
| Runx1 | Validated transcriptional targets of deltaNp63 isoforms | pid | 47 |
| Runx1 | Pathways in cancer | kegg | 321 |
| Runx1 | Chronic myeloid leukemia | kegg | 69 |
| Runx1 | Acute myeloid leukemia | kegg | 53 |
| Enhancer ID | Position | Tissue | Cell | Disease |
|---|---|---|---|---|
| E_03188 | chr5:107680655-107682655 | bone marrow | hematopoietic stem cell | NA |
| E_03189 | chr5:107680655-107682655 | bone marrow | hematopoietic stem cell | NA |
| E_03191 | chr5:107680655-107682655 | bone marrow | hematopoietic stem cell | NA |
| E_03259 | chr5:107680655-107682655 | blood / hematopoietic system | T cell | NA |
| E_03260 | chr5:107680655-107682655 | blood / hematopoietic system | T cell | NA |